U-47700, sold on the street under names like pink, is a synthetic opioid that the Drug Enforcement Administration placed into Schedule I of the Controlled Substances Act because it has a high potential for abuse and no accepted medical use in the United States, according to the Schedule I listing in 21 CFR 1308.11. For employers, treatment programs, and testing sites, the practical question is simpler and harder at the same time: will a drug test catch it. The short answer is that a standard immunoassay panel almost never will, and understanding why matters for how a program should respond when something looks wrong but the cup or dip card comes back negative.
Why standard opioid strips miss U-47700
Rapid immunoassay strips work by targeting antibodies to a specific chemical shape. A morphine class opiate strip is built to react to compounds that share the phenanthrene backbone found in morphine, codeine, and heroin metabolites. An oxycodone strip targets a different but related opioid structure. Fentanyl strips are built around the fentanyl molecule's own anilide piperidine structure. U-47700 is chemically unrelated to all of these families. It belongs to a different class of synthetic opioid agonists first developed decades ago as a research compound and never approved as a medication. Because the antibodies in a standard cup or dip card are not built to recognize that shape, the DEA list of scheduled controlled substances places U-47700 in Schedule I as its own distinct entry, separate from both the morphine class opiates and from fentanyl, which is exactly the signal that a generic opiate or fentanyl immunoassay was never designed to flag it.
This is the same pattern seen across a wave of newer synthetic opioids. Research summarized by the National Institute on Drug Abuse's overview of commonly used drugs notes that novel synthetic opioids are frequently structurally distinct from the opioids that standard workplace panels were built around decades ago, which is why panel design has to keep pace with new compounds rather than assuming one opiate strip covers the whole opioid category. A program that only screens with a basic 5 panel cup, an opiate dip card, or a fentanyl strip is screening for the opioids that strip targets, not for every opioid that could be present.
What a rapid panel can and cannot tell you
The table below summarizes how common rapid test formats behave against U-47700, based on what each antibody class is built to detect.
| Test format | Target | Detects U-47700 |
|---|---|---|
| Standard opiate strip (morphine class) | Morphine, codeine, heroin metabolite | No |
| Oxycodone strip | Oxycodone and oxymorphone | No |
| Fentanyl strip | Fentanyl and some analogs | No, unless the specific strip is validated against it |
| Expanded designer opioid send out panel | Named list of novel synthetic opioids including U-47700 when ordered | Yes, when the lab's target list includes it |
| Lab confirmation by LC MS/MS with U-47700 as a named target | Exact molecule | Yes |
A negative result on a standard opiate dip card or a fentanyl test strip does not mean the donor used nothing. It means the donor's sample did not contain a substance that strip's antibody reacts to, at a concentration above its cutoff. That distinction matters when a collector or supervisor has direct observation of impairment, paraphernalia, or a medical event that points toward opioid use, yet the panel comes back clean.
What a program should do when symptoms suggest an opioid but the panel is negative
This is where the testing side, not the clinical side, has a defined path. Employers and treatment programs should never attempt to diagnose or treat suspected use themselves; that is a medical and emergency response question. What the testing program controls is the specimen chain. When reasonable suspicion or post incident circumstances point to opioid use that a standard panel did not confirm, the collected specimen should be routed to a laboratory for an expanded designer opioid or novel psychoactive substance panel rather than relied on as cleared. A laboratory confirmation testing service can run liquid chromatography tandem mass spectrometry, the method capable of identifying the exact molecule rather than a class, and only that result should be treated as conclusive. Programs that already use higher count panels built for this situation, such as a 17 panel drug test cup, still get broader coverage of common drug classes at the rapid screening stage, but even those cups do not substitute for a targeted lab send out when a specific designer opioid is suspected.
Any non negative or medically unexplained result still has to pass through a Medical Review Officer before an employer takes action. The MRO reviews prescription documentation and legitimate medical explanations before a result is reported as verified positive, and nothing in this process should be shortened or skipped because a case feels urgent.
Confirmation testing and chain of custody
Because U-47700 is not on most standard immunoassay target lists, confirmation depends on telling the laboratory what to look for or using a lab that already screens broadly for emerging synthetic opioids. Collection sites should use proper chain of custody forms and tamper evident packaging so a specimen can legally move from a rapid screen to a confirmation lab without question about integrity. A specimen collection cup with built in adulteration strips helps establish at collection time whether the sample itself was tampered with, which is a separate question from which drugs the sample contains, but both pieces of information matter if a result is ever challenged.
Context: why this substance matters to testing and treatment programs
U-47700 drew attention from public health authorities because it is a potent opioid agonist associated with overdose risk, which is part of why the DEA used its emergency scheduling authority rather than the standard multi year rulemaking process, as described in the same Federal Register notice. Treatment and recovery programs that monitor clients for opioid use should not assume a clean screen on a standard panel rules out use of a newer synthetic opioid. A treatment center testing program that layers rapid screening with periodic lab confirmation, and that updates its testing menu as new substances emerge, is in a stronger position than one relying on a single opiate strip from several years ago.
Employers building or updating a testing program should also recognize that federal mandates do not require testing for every emerging substance. Outside of the federally regulated DOT testing program described in 49 CFR Part 40, which sets the drug panel, specimen, and MRO procedures for safety sensitive transportation employees, most employers choose their own panel composition. The federal schedule of controlled substances itself, maintained under 21 CFR Part 1308, confirms where a substance like U-47700 sits legally, but it does not dictate which employer panel must include it. That decision belongs to the employer, often in consultation with a testing provider or MRO, based on the population being tested and the substances of concern in that workforce or region.
A general drug of abuse test kit lineup gives a program the rapid screening coverage for the most commonly encountered substances, while a standing relationship with a confirmation laboratory gives it the ability to escalate when circumstances call for it. Neither piece should be treated as optional if a program wants defensible results.
Frequently asked questions
Does a standard 5 panel or 10 panel drug test detect U-47700?
No. Standard panels target morphine class opiates, amphetamines, cocaine metabolite, THC metabolite, and similar common drug classes. U-47700 is a chemically distinct synthetic opioid that those antibodies are not built to recognize.
Will a fentanyl test strip catch U-47700?
Generally no. Fentanyl strips are built around the fentanyl molecule and some close analogs. U-47700 has a different chemical structure, so a fentanyl strip is not a reliable way to screen for it unless the specific product has been validated against that compound.
What test method can actually confirm U-47700?
Laboratory confirmation using liquid chromatography tandem mass spectrometry, often ordered as part of an expanded designer opioid or novel psychoactive substance panel, is the method capable of identifying U-47700 specifically. The laboratory needs to include it on the target list for the result to be meaningful.
Is U-47700 legal to possess or sell in the United States?
No. It is a Schedule I controlled substance under the Controlled Substances Act, meaning federal law treats it as having a high potential for abuse and no accepted medical use. Specific state law may add its own penalties, and employers and testing programs should rely on the federal scheduling record rather than assume any particular state treats it differently.
If an employee's screen is negative but behavior suggests opioid impairment, what should an employer do?
Follow the program's reasonable suspicion or post incident protocol, prioritize employee safety and any needed medical response, and send the collected specimen for expanded laboratory confirmation rather than treating a negative rapid screen as the final answer. Any eventual non negative lab result still goes through Medical Review Officer review before it affects employment decisions.
Do rapid test manufacturers update their strips to catch new synthetic opioids?
Coverage varies by manufacturer and by product, and strip target lists do not automatically expand to include every newly scheduled compound. Buyers who need coverage for a specific emerging substance should confirm with the testing provider or laboratory which analytes a given panel or send out test actually targets rather than assume broad coverage.
Related reading: Nitazenes and Drug Testing: The Synthetic Opioids Standard Panels Miss and The Medical Review Officer (MRO) Process Explained for Employers.
This article is general information for employers and testing programs, not legal or medical advice. Testing panel selection, reasonable suspicion protocols, and response to a suspected overdose should be developed with qualified legal counsel, a Medical Review Officer, and emergency medical guidance as appropriate.
